Hyperlipidemia Caused by Voriconazole: A Case Report
Jiasheng Wu,1,2,* Na Chen,3,* Yake Yao,1 Jianying Zhou,1 Hua Zhou1 1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, People’s Republic of China; 2Department of Respiratory and Critical C...
Main Authors: | Wu J, Chen N, Yao Y, Zhou J, Zhou H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-02-01
|
Series: | Infection and Drug Resistance |
Subjects: | |
Online Access: | https://www.dovepress.com/hyperlipidemia-caused-by-voriconazole-a-case-report-peer-reviewed-article-IDR |
Similar Items
-
The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia
by: Peijun Yvonne Zhou, et al.
Published: (2020-06-01) -
Rechallenge of voriconazole successfully tolerated after hepatic toxicity
by: O. Narumoto, et al.
Published: (2020-01-01) -
Chronic pulmonary aspergillosis - case series and review of Indian literature
by: Vikas Marwah, et al.
Published: (2021-01-01) -
Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention
by: Ranjot Kaur, et al.
Published: (2021-01-01) -
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain
by: Grau S, et al.
Published: (2016-12-01)